WO2009020565A1 - Use of phosphates to treat neuroblastomas and medullogastomas - Google Patents
Use of phosphates to treat neuroblastomas and medullogastomas Download PDFInfo
- Publication number
- WO2009020565A1 WO2009020565A1 PCT/US2008/009330 US2008009330W WO2009020565A1 WO 2009020565 A1 WO2009020565 A1 WO 2009020565A1 US 2008009330 W US2008009330 W US 2008009330W WO 2009020565 A1 WO2009020565 A1 WO 2009020565A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ligand
- subject
- acid
- compound
- phosphatase
- Prior art date
Links
- 206010029260 Neuroblastoma Diseases 0.000 title claims abstract description 34
- 229910019142 PO4 Inorganic materials 0.000 title description 4
- 235000021317 phosphate Nutrition 0.000 title description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 title description 2
- 239000003446 ligand Substances 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 33
- 208000000172 Medulloblastoma Diseases 0.000 claims abstract description 31
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims abstract description 16
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 87
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 49
- 229930002330 retinoic acid Natural products 0.000 claims description 49
- -1 antimonyl tartrate Chemical compound 0.000 claims description 28
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 25
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical group [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 25
- 229960000604 valproic acid Drugs 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 102000003964 Histone deacetylase Human genes 0.000 claims description 19
- 108090000353 Histone deacetylase Proteins 0.000 claims description 19
- 125000000304 alkynyl group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 102000027483 retinoid hormone receptors Human genes 0.000 claims description 12
- 108091008679 retinoid hormone receptors Proteins 0.000 claims description 12
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims description 7
- GXEKYRXVRROBEV-FBXFSONDSA-N (1r,2s,3r,4s)-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid Chemical compound C1C[C@@H]2[C@@H](C(O)=O)[C@@H](C(=O)O)[C@H]1O2 GXEKYRXVRROBEV-FBXFSONDSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 229960001727 tretinoin Drugs 0.000 claims description 6
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 5
- 229960001614 levamisole Drugs 0.000 claims description 5
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 claims description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- 229940116193 Protein phosphatase inhibitor Drugs 0.000 claims description 4
- 229940095758 cantharidin Drugs 0.000 claims description 4
- 229930008397 cantharidin Natural products 0.000 claims description 4
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims description 4
- NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 claims description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 4
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 claims description 3
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 claims description 3
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- 150000003892 tartrate salts Chemical class 0.000 claims description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 3
- ZCVAOQKBXKSDMS-PVAVHDDUSA-N (+)-trans-(S)-allethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(CC=C)C(=O)C1 ZCVAOQKBXKSDMS-PVAVHDDUSA-N 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- ZVEMACCDKBQNGX-KALODSIISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid Chemical compound CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N ZVEMACCDKBQNGX-KALODSIISA-N 0.000 claims description 2
- LLOKIGWPNVSDGJ-AFBVCZJXSA-N (3s,6s,9s,12r)-3,6-dibenzyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 LLOKIGWPNVSDGJ-AFBVCZJXSA-N 0.000 claims description 2
- NJOGICJCSWVJKS-MDZDMXLPSA-N 1-[11-hydroxy-2-[(e)-4-[4-hydroxy-2-[1-hydroxy-3-(3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl)butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4h-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-4-methyl-1,7-dioxaspiro[5.5]undec-4-en-8-yl]propan-2-one Chemical compound O1C2(OCCCC2)CCC(C)C1C(C)CC(O)C(C(C(O)C1O2)=C)OC1CCC2(O1)CCC1\C=C\C(C)C(O1)CC(C)=CC21OC(CC(C)=O)CCC2O NJOGICJCSWVJKS-MDZDMXLPSA-N 0.000 claims description 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims description 2
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims description 2
- HTHGAIADRJRJOY-UHFFFAOYSA-N 6-(4-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC(Br)=CC=C1C1N=C2SCCN2C1 HTHGAIADRJRJOY-UHFFFAOYSA-N 0.000 claims description 2
- 241001550224 Apha Species 0.000 claims description 2
- WJIPXHXGFHECTD-UHFFFAOYSA-N C1=CC2=NC=CC2=C2NC(N)=NC(N)=C21 Chemical class C1=CC2=NC=CC2=C2NC(N)=NC(N)=C21 WJIPXHXGFHECTD-UHFFFAOYSA-N 0.000 claims description 2
- 102000004631 Calcineurin Human genes 0.000 claims description 2
- 108010042955 Calcineurin Proteins 0.000 claims description 2
- 239000005946 Cypermethrin Substances 0.000 claims description 2
- 239000005892 Deltamethrin Substances 0.000 claims description 2
- 108010002156 Depsipeptides Proteins 0.000 claims description 2
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 claims description 2
- 102000012749 Dopamine and cAMP-Regulated Phosphoprotein 32 Human genes 0.000 claims description 2
- 108010090047 Dopamine and cAMP-Regulated Phosphoprotein 32 Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- DIAQQISRBBDJIM-DRSCAGMXSA-N Microcystin la Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](C)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 DIAQQISRBBDJIM-DRSCAGMXSA-N 0.000 claims description 2
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 claims description 2
- IOUVKUPGCMBWBT-DARKYYSBSA-N Phloridzin Natural products O[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-DARKYYSBSA-N 0.000 claims description 2
- 102000004097 Protein phosphatase inhibitor 1 Human genes 0.000 claims description 2
- 108090000506 Protein phosphatase inhibitor 1 Proteins 0.000 claims description 2
- RFCWHQNNCOJYTR-IRCAEPKSSA-N Tautomycin Chemical compound O([C@H]([C@H](CC1)C)[C@H](C)CC[C@H](O)[C@H](C)C(=O)C[C@@H](O)[C@@H](OC)[C@H](OC(=O)C[C@@H](O)C=2C(OC(=O)C=2C)=O)C(C)C)[C@@]21CC[C@@H](C)[C@H](CC[C@H](C)C(C)=O)O2 RFCWHQNNCOJYTR-IRCAEPKSSA-N 0.000 claims description 2
- RFCWHQNNCOJYTR-UHFFFAOYSA-N Tautomycin Natural products CC=1C(=O)OC(=O)C=1C(O)CC(=O)OC(C(C)C)C(OC)C(O)CC(=O)C(C)C(O)CCC(C)C(C(CC1)C)OC21CCC(C)C(CCC(C)C(C)=O)O2 RFCWHQNNCOJYTR-UHFFFAOYSA-N 0.000 claims description 2
- GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 claims description 2
- LLOKIGWPNVSDGJ-UHFFFAOYSA-N Trapoxin B Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 LLOKIGWPNVSDGJ-UHFFFAOYSA-N 0.000 claims description 2
- ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2s)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 claims description 2
- FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 claims description 2
- 229960001901 bioallethrin Drugs 0.000 claims description 2
- 229930182747 calyculin Natural products 0.000 claims description 2
- 229930008399 cantharidic acid Natural products 0.000 claims description 2
- UXJFDYIHRJGPFS-WPWMEQJKSA-N chembl380797 Chemical compound C=1C=CC=C(\N=C\C=2C3=CC=CC=C3C=CC=2O)C=1C(=O)NC(C)C1=CC=CC=C1 UXJFDYIHRJGPFS-WPWMEQJKSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- JIGDOBKZMULDHS-UHFFFAOYSA-N cyanogenosin-RR Natural products N1C(=O)C(CCCN=C(N)N)NC(=O)C(C)C(C(O)=O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(=C)N(C)C(=O)CCC(C(O)=O)NC(=O)C(C)C1C=CC(C)=CC(C)C(OC)CC1=CC=CC=C1 JIGDOBKZMULDHS-UHFFFAOYSA-N 0.000 claims description 2
- 108010073357 cyanoginosin LR Proteins 0.000 claims description 2
- 108010079497 cyanoginosin-LA Proteins 0.000 claims description 2
- 229960005424 cypermethrin Drugs 0.000 claims description 2
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002483 decamethrin Drugs 0.000 claims description 2
- OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 claims description 2
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 claims description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- 229950010404 fostriecin Drugs 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- ZZDBMDNRQQDSKG-UHFFFAOYSA-N methyl 5-bromo-1-benzofuran-2-carboxylate Chemical compound BrC1=CC=C2OC(C(=O)OC)=CC2=C1 ZZDBMDNRQQDSKG-UHFFFAOYSA-N 0.000 claims description 2
- CJIASZBWXIFQMU-LNXRSHCCSA-N microcystin LW Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 CJIASZBWXIFQMU-LNXRSHCCSA-N 0.000 claims description 2
- 108010004476 microcystin RR Proteins 0.000 claims description 2
- JIGDOBKZMULDHS-UUHBQKJESA-N microcystin RR Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 JIGDOBKZMULDHS-UUHBQKJESA-N 0.000 claims description 2
- JIGDOBKZMULDHS-HZJVMCKBSA-N microcystin RR Natural products CO[C@@H](Cc1ccccc1)[C@@H](C)C=C(C)C=C[C@@H]2NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](C)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)C(=C)N(C)C(=O)CC[C@@H](NC(=O)[C@H]2C)C(=O)O)C(=O)O JIGDOBKZMULDHS-HZJVMCKBSA-N 0.000 claims description 2
- CYAJEMFRSQGFIG-ISWIILBPSA-N microcystin-LA Natural products CO[C@@H](Cc1ccccc1)[C@@H](C)C=C(C)C=C[C@H](NC(=O)CNC(=O)[C@@H](C)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)C(=C)N(C)C(=O)CC[C@@H](C)C(=O)O)C(=O)O)[C@H](C)C(=O)N CYAJEMFRSQGFIG-ISWIILBPSA-N 0.000 claims description 2
- ZYZCGGRZINLQBL-GWRQVWKTSA-N microcystin-LR Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 ZYZCGGRZINLQBL-GWRQVWKTSA-N 0.000 claims description 2
- DIDLWIPCWUSYPF-UHFFFAOYSA-N microcystin-LR Natural products COC(Cc1ccccc1)C(C)C=C(/C)C=CC2NC(=O)C(NC(CCCNC(=N)N)C(=O)O)NC(=O)C(C)C(NC(=O)C(NC(CC(C)C)C(=O)O)NC(=O)C(C)NC(=O)C(=C)N(C)C(=O)CCC(NC(=O)C2C)C(=O)O)C(=O)O DIDLWIPCWUSYPF-UHFFFAOYSA-N 0.000 claims description 2
- 108010013128 microcystin-LW Proteins 0.000 claims description 2
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical class [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 claims description 2
- OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 claims description 2
- NJOGICJCSWVJKS-UHFFFAOYSA-N norokadanone Natural products O1C2(OCCCC2)CCC(C)C1C(C)CC(O)C(C(C(O)C1O2)=C)OC1CCC2(O1)CCC1C=CC(C)C(O1)CC(C)=CC21OC(CC(C)=O)CCC2O NJOGICJCSWVJKS-UHFFFAOYSA-N 0.000 claims description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004448 pentamidine Drugs 0.000 claims description 2
- 229960000490 permethrin Drugs 0.000 claims description 2
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 claims description 2
- BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 claims description 2
- 229950009215 phenylbutanoic acid Drugs 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 claims description 2
- IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 claims description 2
- 235000019139 phlorizin Nutrition 0.000 claims description 2
- 102000006241 protein phosphatase inhibitor-2 Human genes 0.000 claims description 2
- 108020004098 protein phosphatase inhibitor-2 Proteins 0.000 claims description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 2
- LCOIAYJMPKXARU-VAWYXSNFSA-N salubrinal Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\C1=CC=CC=C1 LCOIAYJMPKXARU-VAWYXSNFSA-N 0.000 claims description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 2
- 239000011775 sodium fluoride Substances 0.000 claims description 2
- 235000013024 sodium fluoride Nutrition 0.000 claims description 2
- YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 claims description 2
- 229960001567 sodium stibogluconate Drugs 0.000 claims description 2
- 229960005314 suramin Drugs 0.000 claims description 2
- 108010060597 trapoxin A Proteins 0.000 claims description 2
- GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 claims description 2
- 108010060596 trapoxin B Proteins 0.000 claims description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 claims description 2
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003681 vanadium Chemical class 0.000 claims description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000237 vorinostat Drugs 0.000 claims description 2
- UZCQCEODMVDIJR-UHFFFAOYSA-N benzyl n-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CC=C1 UZCQCEODMVDIJR-UHFFFAOYSA-N 0.000 claims 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims 1
- 108010033040 Histones Proteins 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 56
- 238000011282 treatment Methods 0.000 description 29
- 230000035755 proliferation Effects 0.000 description 21
- 230000004663 cell proliferation Effects 0.000 description 19
- 239000003981 vehicle Substances 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000011579 SCID mouse model Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 108010077544 Chromatin Proteins 0.000 description 5
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 210000003483 chromatin Anatomy 0.000 description 5
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000005056 compaction Methods 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 108010074724 histone deacetylase 3 Proteins 0.000 description 3
- 229960005280 isotretinoin Drugs 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000005189 alkyl hydroxy group Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 1
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- DJIOGHZNVKFYHH-UHFFFAOYSA-N 2-hexadecylpyridine Chemical compound CCCCCCCCCCCCCCCCC1=CC=CC=N1 DJIOGHZNVKFYHH-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical compound [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- KBUHKLGVLUHYJL-UHFFFAOYSA-N 4-(5,5,8,8-tetramethyl-6,7-dihydroanthracen-2-yl)benzoic acid Chemical compound C=1C=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=CC=1C1=CC=C(C(O)=O)C=C1 KBUHKLGVLUHYJL-UHFFFAOYSA-N 0.000 description 1
- QBEDXUHDXKEDES-SNVBAGLBSA-N 4-[(6s)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazol-6-yl]phenol Chemical compound C1=CC(O)=CC=C1[C@@H]1N=C2SCCN2C1 QBEDXUHDXKEDES-SNVBAGLBSA-N 0.000 description 1
- LKUHOPIEBQOBPT-UHFFFAOYSA-N 4-[1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C1(C=2C=CC(=CC=2)C(O)=O)CC1 LKUHOPIEBQOBPT-UHFFFAOYSA-N 0.000 description 1
- QDSXVZMDVWIEJZ-UHFFFAOYSA-N 4-[2-methyl-1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound C=1C(C(CCC2(C)C)(C)C)=C2C=C(C)C=1C(=C(C)C)C1=CC=C(C(O)=O)C=C1 QDSXVZMDVWIEJZ-UHFFFAOYSA-N 0.000 description 1
- UHFICAKXFHFOCN-UHFFFAOYSA-N 6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalene-2-carboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=CC(C=3C=C4C(C)(C)CCC(C4=CC=3)(C)C)=CC=C21 UHFICAKXFHFOCN-UHFFFAOYSA-N 0.000 description 1
- DPVGXUNWCVEIGT-UHFFFAOYSA-N 6-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dithiolan-2-yl]naphthalene-2-carboxylic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C1(C=2C=C3C=CC(=CC3=CC=2)C(O)=O)SCCS1 DPVGXUNWCVEIGT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- BBSRQTSDRDHGQF-UHFFFAOYSA-M CCN(CC1)CCN1C(c1c(cc2)[o]c2c1C([O-])=O)=O Chemical compound CCN(CC1)CCN1C(c1c(cc2)[o]c2c1C([O-])=O)=O BBSRQTSDRDHGQF-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229940122964 Deacetylase inhibitor Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 1
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- NJJPJDCYPCCRLT-UHFFFAOYSA-N O=C(CCCCCNC(c1ccccc1S)=O)Nc1cccnc1 Chemical compound O=C(CCCCCNC(c1ccccc1S)=O)Nc1cccnc1 NJJPJDCYPCCRLT-UHFFFAOYSA-N 0.000 description 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010082820 apicidin Proteins 0.000 description 1
- 229930186608 apicidin Natural products 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- RWYREGSYPCNZTL-UHFFFAOYSA-N cd564 Chemical compound C1=C(C(O)=O)C=CC2=CC(C(=O)C=3C=C4C(C)(C)CCC(C4=CC=3)(C)C)=CC=C21 RWYREGSYPCNZTL-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 150000004707 phenolate Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-H suramin(6-) Chemical compound [O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O)C)C=CC=3)C)=CC=C(S([O-])(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-H 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Neuroblastoma probaby derives from primitive sympathetic neural precursors. About half of all neuroblastomas arise in the adrenal medulla, and the rest originate in the paraspinal sympathetic ganglia in the chest or abdomen, or in pelvic ganglia. Neuroblastomas account for 7-10% of all childhood cancers and are the most common cancer diagnosed during infancy with the prevalence about one case in 7,000 live births with 700 new cases per year in the United States. This incidence is fairly uniform throughout the world, at least for industrial nations. The median age at diagnosis for neuroblastoma patients is about 18 months, so approximately 40% are diagnosed by one year of age, 75% by four years of age and 98% by ten years of age.
- Medulloblastomas are the most common malignant brain tumors of childhood accounting for more than 20% of pediatric brain tumors. They show both neuronal and glial differentiation. Multimodality treatment including surgery, radio- and chemotherapy have greatly improved the survival of this neoplasm, but more than one third of children with medulloblastomas still die within five years of diagnosis. The remaining survivors experience significant toxicities secondary to therapy. Radiation to the brain is an important component of effective treatment, yet administration of effective radiation doses to children three years or younger frequently results in significant impairment of cognitive ability. Thus in young children, development of new chemotherapy regimens that would provide disease control at least until the child reaches age three and may receive appropriate radiation with reduced chance of severe impairment of neurological function are needed. Antitumor agents which confer potential for long-term survival and have limited toxiticities are thus far lacking. The subject application provides novel methods of treating neuroblastomas and medulloblastomas .
- the invention disclosed herein provides a method of treating a subject suffering from a neuroblastoma or a medulloblastoma comprising administering to the subject one or more phosphatase ligand, alone or in combination with one or more retinoid receptor ligand, or one or more histone deacetylase ligand, or both, in each case in an amount effective to treat the subject.
- the invention disclosed herein provides a method of treating a subject suffering from a neuroblastoma or a medulloblastoma comprising administering to the subject one or more histone deacetylase ligand, alone or in combination with one or more retinoid receptor ligand, or one or more phosphatase ligand, or both, in each case in an amount effective to treat the subject.
- FIG. 1 Treatment with Compound 100 inhibits proliferation of neuroblastoma cells.
- the neuroblastoma cell line, SH-SY5Y was exposed to Compound 100 for 4 or 7 days at concentrations of l ⁇ M (squares), 5 ⁇ M (triangles), lO ⁇ M (short dashed line) , 20 ⁇ M (diamonds) , 50 ⁇ M (long dashed line) or vehicle only (circles) .
- FIG. 1 Treatment with Compound 100 and ATRA inhibits proliferation of neuroblastoma cells.
- the neuroblastoma cell line, SH-SY5Y was exposed to 5 ⁇ M Compound 100 (squares), 25 ⁇ M ATRA (circles), the combination of 5 ⁇ M Compound 100 and 25 ⁇ M ATRA (dashed line) or vehicle only (black line) for 4 or 7 days .
- FIG. 3 Treatment with a combination of Compound 100, ATRA and valproic acid severely inhibits proliferation of neuroblastoma cells.
- the neuroblastoma cell line, SH-SY5Y was exposed to lO ⁇ M Compound 100 (squares), 2.5mM valproic acid (circles) , lO ⁇ M ATRA (triangles) , lO ⁇ M Compound 100 and 2.5mM valproic acid (large dashed line), 2.5mM valproic acid and lO ⁇ M ATRA (small dashed line) , lO ⁇ M Compound 100 and lO ⁇ M ATRA (dashed and dotted line), lO ⁇ M Compound 100, 2.5mM valproic acid and lO ⁇ M ATRA (black line) or vehicle alone (diamonds) for 3 or seven days.
- FIG. 4 Treatment with Compound 100 inhibits proliferation of medulloblastoma cells.
- the medulloblastoma cell line, DAOY was exposed to 20 ⁇ M Compound 100 (squares), 5 ⁇ M Compound 100 (triangles), l ⁇ M Compound 100 (x's) or vehicle only (diamonds) for 3 days.
- FIG. 5 Treatment with ATRA inhibits proliferation of medulloblastoma cells.
- the medulloblastoma cell line, DAOY was exposed to 50 ⁇ M ATRA (squares) , 20 ⁇ M ATRA (triangles), 5 ⁇ M ATRA (X's) or vehicle only (diamonds) for 3 days.
- FIG. 6 Treatment with valproic acid inhibits proliferation of medulloblastoma cells.
- FIG. 7 Treatment with Compound 100 or with Compound 102 inhibits the proliferation of the medulloblastoma cell line DAOY xenograft tumors in SCID mice.
- DAOY cells (5 million) were implanted subcutaneously in the flank of SCID mice (Day 0) .
- FIG. 9 Treatment with Compound 100 or Compound 205 inhibits the proliferation of the neuroblastoma cell line SHSY xenograft in SCID mice.
- SHSY cells (5 million) were implanted subcutaneously in the flank of SCID mice. After the xenografts reached a size of ⁇ 100 cubic mm, treatment was instituted with vehicle alone (control) , compound 100 (1.5mg/kg) or compound 205 (10mg/kg) daily intraperitoneally for 14 days. Xenograft masses were measured day 7 and day 14 of treatment.
- This invention provides a method of treating a subject suffering from neuroblastomas and medulloblastomas, comprising administering to the subject one or more phosphatase ligand, alone or in combination with one or more retinoid receptor ligand, or one or more histone deacetylase ligand, or both, in each case in amounts effective to treat the subject.
- the invention disclosed herein provides a method of treating a subject suffering from a neuroblastoma or a medulloblastoma comprising administering to the subject one or more histone deacetylase ligand, alone or in combination with one or more retinoid receptor ligand, or one or more phosphatase ligand, or both, in each case in an amount effective to treat the subject.
- the phosphatase ligand may be selected from the group consisting of 1-nor-okadaone, antimonyl tartrate, bioallethrin, calcineurin, cantharidic acid, cantharidin, calyculin, cypermethrin, DARPP-32, deamidine, deltamethrin, diaminopyrroloquinazolines, endothal, endothal thioanhydride, fenvalerate, fostriecin, imidazoles, ketoconazole, L-4-bromotetramisole, levamisole, 1-p- bromotetramisole, d-p-bromotetramisole, p- hydroxylevamisole, microcystin LA, microcystin LR, microcystin LW, microcystin RR, molybdate salts, okadaic acid, okadol, norcantharidin, pentamidine, pent
- the phosphatase ligand is a protein phosphatase inhibitor, such as endothal thioanhydride, endothal, norcantharidin or okadaic acid.
- the protein phosphatases of the subject application can be tyrosine-specific, serine/threonine- specific, dual-specificity phosphatases, alkaline phosphatases such as levamisole, and acid phosphatases.
- the phosphatase ligand is a protein phosphatase inhibitor having the structure
- each R n is independently alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
- the protein phosphatase inhibitor described above has the structure
- the histone deacetylase ligand may be an inhibitor, e.g. the histone deacetylase inhibitor HDAC-3 (histone deacetylase-3) .
- the histone deacetylase ligand may also be selected from the group consisting of 2-amino-8-oxo-9, 10-epoxy-decanoyl, 3- (4- aroyl-lH-pyrrol-2-yl) -N-hydroxy-2-propenamide, APHA
- the inhibitor is valproic acid.
- the HDAC inhibitor is a compound having the structure
- the retinoid receptor ligand may be a retinoid, such as a retinoic acid, e.g. cis retinoic acid or trans retinoic acid.
- the cis retinoic acid may be 13-cis retinoic acid and the trans retinoic acid may be all-trans retinoic acid.
- the retinoic acid is all-trans retinoic acid (ATRA) .
- Retinoid receptor ligands used in the method of the invention include vitamin A (retinol) and all its natural and synthetic derivatives (retinoids) .
- the retinoid receptor ligand may be selected from the group consisting of b,g- selective 6- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2- naphthalenyl) -2-naph-thalenecarboxylic acid (TTNN), Z-oxime of 6- (5, 6, 7, 8-tetrahydro-5, 5,8, 8-tetramethyl-2- naphthalenylcarbonyl) -2-naphthalenecarboxylic acid
- SR11254 4- (5, 6, 7, 8-tetrahydro-5, 5,8, 8-tetramethyl-2- anthracenyl) benzoic acid (TTAB), 4- [1- (5, 6, 7, 8-tetrahydro- 5,5,8, 8-tetramethyl-2-naphthalenyl) -cyclopropyl] benzoic acid (SR11246), 4- [ 1- (5, 6, 7, 8-tetrahydro-3, 5, 5, 8, 8- pentamethyl-2-naphthalenyl) -2-methylpropenyl] benzoic acid (SR11345), and 2- ( 6-carboxy-2-naphthalenyl) -2- (5, 6, 7, 8- tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl) -1, 3- dithiolane (SR11253) .
- the subject is a mammal.
- administering an agent may be performed using any of the various methods or delivery systems well known to those skilled in the art.
- the administering can be performed, for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, intrathecally, into a cerebral ventricle, intraventicularly, intratumorally, into cerebral parenchyma or intraparenchchymally .
- compositions in accordance with the invention may be used but are only representative of the many possible systems envisioned for administering compositions in accordance with the invention.
- Injectable drug delivery systems include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g., ethanol, propylene glycol and sucrose) and polymers (e.g., polycaprylactones and PLGA's) .
- solubility-altering agents e.g., ethanol, propylene glycol and sucrose
- polymers e.g., polycaprylactones and PLGA's
- Implantable systems include rods and discs, and can contain excipients such as PLGA and polycaprylactone .
- Oral delivery systems include tablets and capsules. These can contain excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrilodone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (e.g., stearates and talc) .
- excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrilodone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (
- Transmucosal delivery systems include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g., propylene glycol, bile salts and amino acids) , and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid) .
- solubilizers and enhancers e.g., propylene glycol, bile salts and amino acids
- other vehicles e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid
- Dermal delivery systems include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrolidone) .
- the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer.
- Solutions, suspensions and powders for reconstitutable delivery systems include vehicles such as suspending agents
- humectants e.g., gums, zanthans, cellulosics and sugars
- solubilizers e.g., ethanol, water, PEG and propylene glycol
- surfactants e.g., sodium lauryl sulfate, Spans, Tweens, and cetyl pyridine
- preservatives and antioxidants e.g., parabens, vitamins E and C, and ascorbic acid
- anti-caking agents e.g., EDTA
- the compounds described in the present invention are in racemic form or as individual enantiomers.
- the enantiomers can be separated using known techniques, such as those described, for example, in Pure and Applied Chemistry 69, 1469-1474, (1997) IUPAC.
- zwitterion means a compound that is electrically neutral but carries formal positive and negative charges on different atoms. Zwitterions are polar, have high solubility in water and have poor solubility in most organic solvents. The compounds disclosed herein may also form zwitterions For example, a compound having the structure
- Certain embodiments of the disclosed compounds can contain a basic functional group, such as amino or alkylamino, and are thus capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids, or contain an acidic functional group and are thus capable of forming pharmaceutically acceptable salts with bases.
- the instant compounds therefore may be in a salt form.
- a "salt" is a salt of the instant compounds which has been modified by making acid or base salts of the compounds.
- the salt may be pharmaceutically acceptable.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as phenols.
- the salts can be made using an organic or inorganic acid.
- Such acid salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and the like.
- Phenolate salts are the alkaline earth metal salts, sodium, potassium or lithium.
- pharmaceutically acceptable salt in this respect, refers to the relatively non-toxic, inorganic and organic acid or base addition salts of compounds of the present invention.
- salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base or free acid form with a suitable organic or inorganic acid or base, and isolating the salt thus formed.
- Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
- suitable salts see, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19,.
- alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- Ci-C n as in “Ci-C n alkyl” is defined to include groups having 1, 2, ...., n-1 or n carbons in a linear or branched arrangement, and specifically includes methyl, ethyl, propyl, butyl, pentyl, hexyl, and so on.
- An embodiment can be Ci-Ci 2 alkyl.
- Alkoxy represents an alkyl group as described above attached through an oxygen bridge.
- Hydroxyalkyl represents an alkyl group as described aboved with a hydroxyl group.
- Hydroxyalky groups include, for example, (CH 2 ) i-i 0 OH and includes CH 2 OH, CH 2 CH 2 OH, CH 2 CH 2 CH 2 OH and so forth.
- alkenyl refers to a non-aromatic hydrocarbon radical, straight or branched, containing at least 1 carbon to carbon double bond, and up to the maximum possible number of non-aromatic carbon-carbon double bonds may be present.
- C 2 -C n alkenyl is defined to include groups having 1, 2, ...., n-1 or n carbons.
- C 2 -C 6 alkenyl means an alkenyl radical having 2, 3, 4, 5, or 6 carbon atoms, and at least 1 carbon-carbon double bond, and up to, for example, 3 carbon-carbon double bonds in the case of a C 6 alkenyl, respectively.
- Alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl . As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.
- An embodiment can be C 2 -Ci 2 alkenyl.
- alkynyl refers to a hydrocarbon radical straight or branched, containing at least 1 carbon to carbon triple bond, and up to the maximum possible number of non-aromatic carbon-carbon triple bonds may be present.
- C 2 -C n alkynyl is defined to include groups having 1, 2, ...., n-1 or n carbons.
- C 2 -C 6 alkynyl means an alkynyl radical having 2 or 3 carbon atoms, and 1 carbon-carbon triple bond, or having 4 or 5 carbon atoms, and up to 2 carbon-carbon triple bonds, or having 6 carbon atoms, and up to 3 carbon-carbon triple bonds.
- Alkynyl groups include ethynyl, propynyl and butynyl . As described above with respect to alkyl, the straight or branched portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated. An embodiment can be a C 2 -C n alkynyl .
- aryl is intended to mean any stable monocyclic or bicyclic carbon ring of up to 10 atoms in each ring, wherein at least one ring is aromatic.
- aryl elements include phenyl, naphthyl, tetrahydro- naphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.
- the aryl substituent is bicyclic and one ring is non-aromatic, it is understood that attachment is via the aromatic ring.
- the substituted aryls included in this invention include substitution at any suitable position with amines, substituted amines, alkylamines, hydroxys and alkylhydroxys, wherein the "alkyl" portion of the alkylamines and alkylhydroxys is a C 2 -C n alkyl as defined hereinabove.
- the substituted amines may be substituted with alkyl, alkenyl, alkynl, or aryl groups as hereinabove defined.
- alkyl, alkenyl, alkynyl, and aryl substituents may be unsubstituted or unsubstituted, unless specifically defined otherwise.
- a (C ⁇ -C 6 ) alkyl may be substituted with one or more substituents selected from OH, oxo, halogen, which includes F, Cl, Br, and I, alkoxy, dialkylamino, or heterocyclyl, such as morpholinyl, piperidinyl, and so on.
- alkyl, alkenyl, and alkynyl groups can be further substituted by replacing one or more hydrogen atoms by non-hydrogen groups described herein to the extent possible. These include, but are not limited to, halo, hydroxy, mercapto, amino, carboxy, cyano and carbamoyl .
- substituted means that a given structure has a substituent which can be an alkyl, alkenyl, or aryl group as defined above.
- the term shall be deemed to include multiple degrees of substitution by a named substitutent .
- the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally.
- independently substituted it is meant that the (two or more) substituents can be the same or different.
- terapéuticaally effective amount means an amount sufficient to treat a subject afflicted with a disease (e.g. neuroblastoma or medulloblastoma) or to alleviate a symptom or a complication associated with the disease.
- a disease e.g. neuroblastoma or medulloblastoma
- alleviate a symptom or a complication associated with the disease e.g. neuroblastoma or medulloblastoma
- treating means slowing, stopping or reversing the progression of a disease, particularly neuroblastoma and medulloblastoma.
- Histones are groups of proteins which associate with DNA in eukaryotic cells to form compacted structures called chromatin. This compaction allows an enormous amount of DNA to be located within the nucleus of a eukaryotic cell, but the compact structure of chromatin restricts the access of transcription factors to the DNA. Acetylation of the histones decreases the compaction of the chromatin allowing transcription factors to bind to the DNA.
- HDACs histone deacetylases
- the human medulloblastoma cell line DAOY is available from the American Type Culture Collection (ATCC), P.O. Box 1549, Manassas, Virginia, 20108, as ATCC No. HTB-186.
- the cantharidin homolog that was evaluated was the Compound 100, which was obtained from Lixte Biotechnology Holdings, Inc., 248 Route 25A, No. 2, East Setauket, New York, which has the structure:
- the neuroblastoma cell line, SHSY5Y was exposed to the cantharidin analog Compound 100 for 4 or 7 days at concentrations of 1, 5, 10, 20 and 50 ⁇ M.
- l ⁇ M and 5 ⁇ M there was little or no inhibition of cell proliferation at day 4 and enhanced cell growth by day 7 as compared to cells exposed to vehicle (media) alone (Figure 1.)
- Dose dependent inhibition was observed at day 4 at the three higher doses with escape of growth inhibition for doses less than 50 ⁇ M by day 7.
- Compound 100 like several other known protein phosphatase inhibitors, slightly stimulates cellular proliferation (Yi et al., 1988 and Wang, 1989)
- Cells treated with 2.5mM valproic acid and lO ⁇ M ATRA exhibited inhibition of proliferation ( Figure 3, short dashed line); however the cells treated with 2.5mM valproic acid and 10 ⁇ M Compound 100 (Figure 3, long dashed line), lO ⁇ M ATRA and lO ⁇ M Compound 100 ( Figure 3, dashed- dotted line) or 2.5mM valproic acid, lO ⁇ M ATRA and lO ⁇ M Compound 100 ( Figure 3, black line) exhibited high levels of proliferation inhibition, indicating that Compound 100 synergistically enhanced the activity of ATRA, valproic acid and valproic acid in combination with ATRA.
- Compound 100 inhibits the proliferation of the neuroblastoma cell line SHSY when SHSY cells are implanted in SCID mice ( Figure 9) .
- Example 2 Effect of cantharidin analogs on DAOY Cells
- the medulloblastoma cell line, DAOY was exposed to the cantharidin analog, Compound 100 at concentrations of l ⁇ M, 5 ⁇ M and 20 ⁇ M and evaluated for cellular proliferation over the course of three days.
- DAOY cells treated with vehicle only (media) exhibited no change in cellular proliferation while the DAOY cells treated with Compound 100 all had decreased rates of cellular proliferation as compared to the control, with the cells treated with 20 ⁇ M Compound 100 exhibiting the greatest decrease in cellular proliferation ( Figure 4, squares) . Therefore, Cmpound 100 even at low concentration is capable of preventing cellular proliferation.
- Compound 100 and Compound 102 both inhibit the proliferation of DAOY cells when implanted subcutaneously in SCID mice ( Figure 7) .
- the HDAC inhibitor that was evaluated was the Compound 205, which was obtained from Lixte Biotechnology Holdings, Inc., 248 Route 25A, No. 2, East Setauket, New York, which has the structure:
- the medulloblastoma cell line, DAOY was exposed to the HDAC inhibitor, Compound 205 at lO ⁇ M, ATRA at 50 ⁇ M, and the compound 205 at lO ⁇ M combined with ATRA at 50 ⁇ M, and evaluated for cellular proliferation over the course of seven days.
- DAOY cells treated with vehicle only (media) exhibited no change in cellular proliferation while the DAOY cells treated with Compound 205 alone and ATRA alone all had decreased rates of cellular proliferation as compared to the control.
- DAOY cells treated with compound 205 in combination with ATRA had a marked decrease in the rate of cellular proliferation. (Figure 8) Therefore, we have shown that Compound 205 is active against medulloblastoma cell line DAOY.
- We have also shown the Compound 205 in combination with ATRA is synergistically active against medulloblastoma cell line DAOY .
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08794986A EP2185173A4 (en) | 2007-08-03 | 2008-08-01 | Use of phosphatases to treat neuroblastomas and medullogastomas |
AU2008284364A AU2008284364A1 (en) | 2007-08-03 | 2008-08-01 | Use of phosphatases to treat neuroblastomas and medulloblastomas |
CA2718472A CA2718472A1 (en) | 2007-08-03 | 2008-08-01 | Use of phosphatases to treat neuroblastomas and medulloblastomas |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96330707P | 2007-08-03 | 2007-08-03 | |
US60/963,307 | 2007-08-03 | ||
US6397008P | 2008-02-06 | 2008-02-06 | |
US61/063,970 | 2008-02-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009020565A1 true WO2009020565A1 (en) | 2009-02-12 |
WO2009020565A8 WO2009020565A8 (en) | 2009-12-23 |
Family
ID=40338376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/009330 WO2009020565A1 (en) | 2007-08-03 | 2008-08-01 | Use of phosphates to treat neuroblastomas and medullogastomas |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090035292A1 (en) |
EP (1) | EP2185173A4 (en) |
AU (1) | AU2008284364A1 (en) |
CA (1) | CA2718472A1 (en) |
WO (1) | WO2009020565A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009045440A1 (en) | 2007-10-01 | 2009-04-09 | Lixte Biotechnology Holdings, Inc. | Hdac inhibitors |
EP2309853A1 (en) * | 2008-08-01 | 2011-04-20 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
US8541458B2 (en) | 2008-08-01 | 2013-09-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
WO2014168941A1 (en) | 2013-04-09 | 2014-10-16 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
US9079917B2 (en) | 2007-02-06 | 2015-07-14 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US9526915B2 (en) | 2008-08-01 | 2016-12-27 | John S. Kovach | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
US9833450B2 (en) | 2015-02-19 | 2017-12-05 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
US9988394B2 (en) | 2015-05-15 | 2018-06-05 | Lixte Biotechnology Inc. | Oxabicycloheptane prodrugs |
US10071094B2 (en) | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
US10149847B2 (en) | 2012-06-29 | 2018-12-11 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
WO2010014220A1 (en) * | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
EP2366398A1 (en) * | 2010-03-17 | 2011-09-21 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with an HDAC inhibitor |
WO2016168647A1 (en) * | 2015-04-17 | 2016-10-20 | Acetylon Pharmaceuticals Inc. | Treatment of neuroblastoma with histone deacetylase inhibotrs |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326898A (en) * | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
US20040161475A1 (en) * | 1997-10-15 | 2004-08-19 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
US20050272644A1 (en) * | 2002-07-25 | 2005-12-08 | Yih-Lin Chung | Method for increasing therapeutic gain in radiotherapy and chemotherapy |
US20070155751A1 (en) * | 2002-09-23 | 2007-07-05 | Schering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4143054A (en) * | 1977-11-04 | 1979-03-06 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane- and 7-oxabicycloheptene compounds |
US4218478A (en) * | 1979-01-05 | 1980-08-19 | Ruiko Oiwa | Trichostatin as an antiprotozoal agent |
US4298752A (en) * | 1980-09-19 | 1981-11-03 | Regents Of The University Of California | Cycloadduct precursors of cantharidin and method |
US4614825A (en) * | 1982-05-17 | 1986-09-30 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane and 7-oxabicycloheptene compounds |
US4463015A (en) * | 1982-08-18 | 1984-07-31 | E. R. Squibb & Sons, Inc. | Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation |
JPS61176523A (en) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | Carcinostatic agent |
US4654355A (en) * | 1985-08-01 | 1987-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs |
US4851553A (en) * | 1986-06-04 | 1989-07-25 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane amido-carboxylic acids |
US6222055B1 (en) * | 1995-07-06 | 2001-04-24 | Fraunhofer-Gesellschaft Zur Foerderung Der Angwandten Forschung E.V. | Hydrolyzable and polymerizable and/or polyadditive silanes |
US6777217B1 (en) * | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US6387673B1 (en) * | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
US20040110822A1 (en) * | 1998-07-14 | 2004-06-10 | The University Of Newcastle Research Associates | Anhydride modified cantharidin analogues useful in the treatment of cancer |
US20020151515A1 (en) * | 1999-06-18 | 2002-10-17 | Roberts Bruce L. | Preparation and use of superior vaccines |
US6949624B1 (en) * | 1999-08-03 | 2005-09-27 | The United States Of America As Represented By The Department Of Health And Human Services | Cloning of the human nuclear receptor co-repressor gene |
ATE489360T1 (en) * | 2000-03-24 | 2010-12-15 | Methylgene Inc | HISTONE DEACETYLASE INHIBITORS |
PE20020354A1 (en) * | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
CN1213050C (en) * | 2000-11-23 | 2005-08-03 | 拜尔公司 | Use of oxadicyclo [2.2.1] heptane derivative as pesticide |
AUPR392301A0 (en) * | 2001-03-23 | 2001-04-26 | University Of Newcastle Research Associates Limited, The | Protein phosphatase inhibitors |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US20040010045A1 (en) * | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
US7179450B2 (en) * | 2001-09-20 | 2007-02-20 | Medi-Physics, Inc. | Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe |
CA2463552C (en) * | 2001-10-16 | 2011-05-17 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
AU2003211576A1 (en) * | 2002-02-20 | 2003-09-09 | Sueharu Horinouchi | Histone deacetylase inhibitors and process for producing the same |
US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
DE03768629T1 (en) * | 2002-11-05 | 2006-01-26 | The Regents Of The University Of California, Oakland | METHOD AND MATERIALS FOR THE INVESTIGATION OF PATHS ASSOCIATED WITH GLOBALBLASTOM PROGRESSION |
US20040197888A1 (en) * | 2002-12-31 | 2004-10-07 | Armour Christopher D. | Alternatively spliced isoforms of histone deacetylase 3 (HDAC3) |
WO2004064727A2 (en) * | 2003-01-16 | 2004-08-05 | Georgetown University | Method of cancer treatment using hdac inhibitors |
WO2004109280A2 (en) * | 2003-06-06 | 2004-12-16 | Combinatorx Incorporated | System and method for multidimensional evaluation of combinations of compositions |
US7842835B2 (en) * | 2003-07-07 | 2010-11-30 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
WO2005025620A2 (en) * | 2003-08-13 | 2005-03-24 | Pharmacia Corporation | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents |
US8652502B2 (en) * | 2003-12-19 | 2014-02-18 | Cordis Corporation | Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury |
US20050282893A1 (en) * | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
CA2641308A1 (en) * | 2006-02-06 | 2007-08-16 | Lixte Biotechnology Holdings, Inc. | Use of phosphatases to treat tumors overexpressing n-cor |
US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
US8129340B2 (en) * | 2006-09-08 | 2012-03-06 | Institut Gustave Roussy | Inhibitors of protein phosphatase 1, GADD34 and protein phosphatase 1/GADD34 complex, preparation and uses thereof |
US7998957B2 (en) * | 2007-02-06 | 2011-08-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
EA018618B1 (en) * | 2007-10-01 | 2013-09-30 | Ликсте Байотекнолоджи, Инк. | Hdac inhibitors |
EP2309853A4 (en) * | 2008-08-01 | 2012-04-25 | Lixte Biotechnology Inc | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
-
2008
- 2008-08-01 US US12/221,360 patent/US20090035292A1/en not_active Abandoned
- 2008-08-01 CA CA2718472A patent/CA2718472A1/en not_active Abandoned
- 2008-08-01 WO PCT/US2008/009330 patent/WO2009020565A1/en active Application Filing
- 2008-08-01 EP EP08794986A patent/EP2185173A4/en not_active Withdrawn
- 2008-08-01 AU AU2008284364A patent/AU2008284364A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326898A (en) * | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
US20040161475A1 (en) * | 1997-10-15 | 2004-08-19 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
US20050272644A1 (en) * | 2002-07-25 | 2005-12-08 | Yih-Lin Chung | Method for increasing therapeutic gain in radiotherapy and chemotherapy |
US20070155751A1 (en) * | 2002-09-23 | 2007-07-05 | Schering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
See also references of EP2185173A4 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9079917B2 (en) | 2007-02-06 | 2015-07-14 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US10023587B2 (en) | 2007-02-06 | 2018-07-17 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US10399993B2 (en) | 2007-02-06 | 2019-09-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
EP2200439B1 (en) * | 2007-10-01 | 2017-03-22 | Lixte Biotechnology, Inc. | Hdac inhibitors |
US8455688B2 (en) | 2007-10-01 | 2013-06-04 | Lixte Biotechnology, Inc. | HDAC inhibitors |
WO2009045440A1 (en) | 2007-10-01 | 2009-04-09 | Lixte Biotechnology Holdings, Inc. | Hdac inhibitors |
EP2200439A1 (en) * | 2007-10-01 | 2010-06-30 | Lixte Biotechnology, Inc. | Hdac inhibitors |
US8541458B2 (en) | 2008-08-01 | 2013-09-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
EP2309853A4 (en) * | 2008-08-01 | 2012-04-25 | Lixte Biotechnology Inc | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
US9526915B2 (en) | 2008-08-01 | 2016-12-27 | John S. Kovach | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
EP2309853A1 (en) * | 2008-08-01 | 2011-04-20 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
US10149847B2 (en) | 2012-06-29 | 2018-12-11 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
US10668062B2 (en) | 2012-06-29 | 2020-06-02 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
WO2014168941A1 (en) | 2013-04-09 | 2014-10-16 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
US10532050B2 (en) | 2013-04-09 | 2020-01-14 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
US11931354B2 (en) | 2013-04-09 | 2024-03-19 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
US10071094B2 (en) | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
US10434100B2 (en) | 2014-07-24 | 2019-10-08 | Lixte Biotechnology, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
US10413541B2 (en) | 2015-02-19 | 2019-09-17 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
US9833450B2 (en) | 2015-02-19 | 2017-12-05 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
US10364252B2 (en) | 2015-05-15 | 2019-07-30 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
US9988394B2 (en) | 2015-05-15 | 2018-06-05 | Lixte Biotechnology Inc. | Oxabicycloheptane prodrugs |
US10618908B2 (en) | 2015-05-15 | 2020-04-14 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
US11236102B2 (en) | 2015-05-15 | 2022-02-01 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
US11866444B2 (en) | 2015-05-15 | 2024-01-09 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
Also Published As
Publication number | Publication date |
---|---|
EP2185173A1 (en) | 2010-05-19 |
US20090035292A1 (en) | 2009-02-05 |
AU2008284364A1 (en) | 2009-02-12 |
WO2009020565A8 (en) | 2009-12-23 |
CA2718472A1 (en) | 2009-02-12 |
EP2185173A4 (en) | 2011-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090035292A1 (en) | Use of phosphatases to treat neuroblastomas and medulloblastomas | |
US20170259081A1 (en) | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase | |
US11931354B2 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
US20100029683A1 (en) | Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses | |
UA119537C2 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas | |
US20080214569A1 (en) | Use of phosphatases to treat tumors overexpressing N-CoR | |
CA2641308A1 (en) | Use of phosphatases to treat tumors overexpressing n-cor | |
CA3075719A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
AU2015225436A1 (en) | Use of eribulin and mTOR inhibitors as combination therapy for the treatment of cancer | |
AU2005251588B2 (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
US20090306098A1 (en) | Combination of roscovitine and a hdca inhibitor to treat proliferative diseases | |
EP3407887A1 (en) | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
EP2136631B1 (en) | Methods for treating neoplasia with combination of chemotherapeutic agents and radiation | |
CA3166741A1 (en) | Combination therapy for treating cancer | |
KR20100126453A (en) | Combination anti-cancer agents | |
WO2002036133A1 (en) | New use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08794986 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2718472 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008284364 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008794986 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008284364 Country of ref document: AU Date of ref document: 20080801 Kind code of ref document: A |